Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier, David Hoffmeister, Ronald Matricaria, Per Peterson, Kelli Richard, Mike Gresser

Premium
Invitrogen’s $5M Man
 
Invitrogen CEO and chairman, Greg Lucier, made more than $5.4 million in 2006, according to the company’s proxy statement.
 
His base salary was $904,615, with the balance of his income coming from stock options, incentive payouts, and other compensation. David Hoffmeister, senior vice president and CFO, was the next highest paid executive at the company, pulling in $2.6 million.
 
According to the proxy statement, Ronald Matricaria made $274, 351, making him the highest paid board director after Lucier. The figure includes an annual cash compensation of $75,000, stock options, and other compensation. Four other directors made $246,184. The remaining three directors took home an average of $236,488.
 
On March 1, the company adopted new annual compensation guidelines stating each board director will receive a fixed annual compensation of $250,000 with 30 percent payable in cash and 70 percent in restricted stock.
 
Also, the company said last week Per Peterson has joined its board. Peterson recently retired from Johnson & Johnson as chairman of research and development where he was responsible for the corporate office of science and technology, the R&D council, and J&J’s cell therapy research work. Prior to J&J, he held various positions at Scripps Research Institute, the Wallenberg Laboratory, and the University of Uppsala in Sweden. 
 
The company also announced the appointment of Kelli Richard as vice president, finance and chief accounting officer. Richard has been with Invitrogen since 2005 and was with Gateway before that.
 

 
Oxford Genome Sciences said this week it has appointed Mike Gresser to its scientific advisory board. Gresser is currently a visiting scholar at the Molecular Biology Institute at the University of California, Los Angeles. Before that, he held positions at Amgen as vice president , research for inflammation and head of neuroscience research. Gresser received his PhD in biochemistry from Brandeis University

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.